ImmuCell Corporation ICCC
10.80 USD +0.61 (+5.93%)
Nov 13, 2026, 11:15 AM EST
10.50 Day range 10.81
4.52 52-week range 12.10
- YTD
- +75.61%
- 1 year
- +78.51%
News
benzinga.com ImmuCell Q3 EPS $0.10 Up From $(0.02) YoY, Sales $8.040M Up From $5.506M YoY ImmuCell (NASDAQ:ICCC) reported quarterly earnings of $0.10 per share. This is a 600 percent increase over losses of $(0.02) per share from the same period last year. The company reported $8.040…
globenewswire.com ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2026 PORTLAND, Maine, Nov. 12, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets…
globenewswire.com ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2026 Conference Call Scheduled for Friday, November 13, 2026 at 9:00 AM ET Conference Call Scheduled for Friday, November 13, 2026 at 9:00 AM ET
benzinga.com ImmuCell Reports Q3 Preliminary Sales Of $8M, Up 46% YoY ImmuCell Corporation (NASDAQ:ICCC) ("ImmuCell" or the "Company"), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity,
benzinga.com ImmuCell Reports Q2 2026 Results: Full Earnings Call Transcript ImmuCell (NASDAQ:ICCC) released second-quarter financial results and hosted an earnings call on Friday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensive…
benzinga.com ImmuCell Q2 EPS $0.20 Up From $0.06 YoY, Sales $7.186M Up From $6.445M YoY ImmuCell (NASDAQ:ICCC) reported quarterly earnings of $0.20 per share. This is a 233.33 percent increase over earnings of $0.06 per share from the same period last year. The company reported $7.186…
benzinga.com ImmuCell Q2 Total Product Sales Rises 12% ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity,
benzinga.com ImmuCell Q1 EPS $0.21 Up From $0.16 YoY, Sales $10.357M Up From $8.067M YoY ImmuCell (NASDAQ:ICCC) reported quarterly earnings of $0.21 per share. This is a 31.25 percent increase over earnings of $0.16 per share from the same period last year. The company reported $10.357…
benzinga.com Earnings Scheduled For May 14, 2026 - benzinga.com ImmuCell And Norbrook Laboratories Reach Settlement Agreement, Norbrook To Pay $2M Following Expiration Of 2019 Supply Deal On May 8, 2026, ImmuCell Corporation and Norbrook Laboratories Limited (incorporated and registered in Northern Ireland) entered into a Settlement Deed to resolve and release any and all claims…
- benzinga.com ImmuCell Reports Q1 Preliminary Sales $10.4M Up From 28.4% YoY ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today…
benzinga.com ImmuCell Q4 EPS $(0.31) Down From $0.06 YoY, Sales $7.626M Down From $7.751M YoY ImmuCell (NASDAQ:ICCC) reported quarterly losses of $(0.31) per share. This is a 616.67 percent decrease over earnings of $0.06 per share from the same period last year. The company reported $7.626…- benzinga.com Earnings Scheduled For March 4, 2026
- benzinga.com ImmuCell Reports Q4 Preliminary Net Sales Of $7.6M; Domestic Sales Were $7.0M In 2025, An 8.7% Increase Compared To 2024 ImmuCell Corporation (NASDAQ:ICCC) ("ImmuCell" or the "Company"), an animal health company that develops, manufactures and markets products that improve cattle health and productivity, today…
- benzinga.com ImmuCell Pauses Re-Tain Drug After FDA Setback, Shifts Focus to Expanding First Defense Business ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell"), an animal health company that develops, manufactures and markets products that improve cattle health and productivity today announced that it…
benzinga.com ImmuCell Puts Re-Tain On Pause After FDA Letter Animal health company ImmuCell receives an Incomplete Letter from the FDA for its Re-Tain NADA. Company shifts focus to First Defense.
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session 
benzinga.com ImmuCell Has Decided To Pause Further Investment In Re-Tain In seeking FDA approval to bring its innovative Re-Tain® product to market, ImmuCell received Complete Letters from the FDA for four of the five Technical Sections required for NADA approval. It…
benzinga.com ImmuCell Increasing First Defense Field Sales Force By 50%, Expanding First Defense Production Capabilities After Receiving FDA's Incomplete Letter For Its Re-Tain New Animal Drug Application ImmuCell Corporation (NASDAQ:ICCC) ("ImmuCell"), an animal health company that develops, manufactures and markets products that improve cattle health and productivity today announced that it received…- benzinga.com ImmuCell Q3 EPS $(0.02) Up From $(0.09) YoY, Sales $5.506M Down From $6.012M YoY ImmuCell (NASDAQ:ICCC) reported quarterly losses of $(0.02) per share. This is a 77.78 percent increase over losses of $(0.09) per share from the same period last year. The company reported $5.506…
- benzinga.com Earnings Scheduled For November 13, 2025
benzinga.com ImmuCell Names Olivier te Boekhorst As President And CEO, Effective November 1, 2025, ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve…- benzinga.com ImmuCell Announces Preliminary Q3 2025 Revenue Of $5.5M ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve…
- benzinga.com ImmuCell Selects Olivier Te Boekhorst As Its Next President, CEO, Expected Start Date November 1, 2025 PORTLAND, Maine, Sept. 29, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets…
- benzinga.com ImmuCell Q2 EPS $0.06 Up From $(0.20) YoY, Sales $6.445M Up From $5.473M YoY ImmuCell (NASDAQ:ICCC) reported quarterly earnings of $0.06 per share. This is a 130 percent increase over losses of $(0.20) per share from the same period last year. The company reported $6.445…
- benzinga.com Earnings Scheduled For August 14, 2025
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com Earnings Scheduled For May 14, 2025
- benzinga.com ImmuCell Preliminary Q1 2025 Revenue Of $8.1M Up From $7.3M YoY; Reduced The Backlog Of Orders To $4M As Of March 31, 2025, From $4.4M As Of December 31, 2024 - ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve…
- benzinga.com ImmuCell Q4 EPS $0.06 Up From $(0.15) YoY, Sales $7.75M Up From $5.10M YoY ImmuCell (NASDAQ:ICCC) reported quarterly earnings of $0.06 per share. This is a 140 percent increase over losses of $(0.15) per share from the same period last year. The company reported $7.75…
- benzinga.com Earnings Scheduled For February 25, 2025
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com ImmuCell Settles Insurance Claim For $426K Covering Production Contamination Losses, Adding To $250K Paid In Q3 2023 ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve…
- benzinga.com Reported Earlier, ImmuCell Preliminary Q4 Sales Of $7.8M (+52% YoY) and Fiscal 2024 Of $26.5M (+52% YoY), Driven by Increased Production Preliminary, Unaudited Total Sales Results: 20242023$ Increase% Increase During the Three-Month Periods Ended December 31,$7.8 million$5.1 million$2.7 million52%During the Years Ended December…
- benzinga.com ImmuCell Q3 GAAP EPS $(0.09) Up From $(0.12) YoY, Sales $6.01M Up From $5.40M YoY ImmuCell (NASDAQ:ICCC) reported quarterly losses of $(0.09) per share. This is a 25 percent increase over losses of $(0.12) per share from the same period last year. The company reported $6.01…
- benzinga.com Earnings Scheduled For November 13, 2024
- benzinga.com ImmuCell Announces Preliminary Q3 Revenue Of $6M Up From $5.4M YoY ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve…
benzinga.com PriceSmart, Kura Sushi And 3 Stocks To Watch Heading Into Wednesday - benzinga.com ImmuCell Updates Regulatory Status Of Product Development Initiative For Re-Tain ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com Earnings Scheduled For February 27, 2024 Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million.
- benzinga.com ImmuCell Q3 2023 Gaap EPS $(0.12) Down From $(0.08) YoY, Sales $5.40M Up From $4.80M YoY ImmuCell (NASDAQ:ICCC) reported quarterly losses of $(0.12) per share. This is a 50 percent decrease over losses of $(0.08) per share from the same period last year. The company reported $5.40…
- benzinga.com Earnings Scheduled For November 13, 2023 Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter.
- benzinga.com ImmuCell Announces Preliminary, Unaudited Sales Results For Q3 2023; Sees Q3 Revenue $5.4M Vs 4.8M YoY ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical
- benzinga.com ImmuCell Q2 EPS $(0.18) Down From $(0.09) YoY, Sales $3.53M Down From $3.86M YoY ImmuCell (NASDAQ:ICCC) reported quarterly losses of $(0.18) per share. This is a 100 percent decrease over losses of $(0.09) per share from the same period last year. The company reported $3.53…
- benzinga.com Earnings Scheduled For August 10, 2023 Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million.
- benzinga.com Why ImmuCell Are Trading Higher; Here Are 20 Stocks Moving Premarket Gainers Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) shares surged 131.6% to $4.03 in pre-market trading after gaining 15% on Tuesday.